EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The value of surgery and the prognostic factors for patients with recurrent low-grade endometrial stromal sarcoma: a retrospective study of 38 patients

Chenlian Quan iD, Zhong Zheng iD, Siyu Cao iD, Yong Wu iD, Wei Zhang iD, Yan Huang iD

Journal of Gynecologic Oncology · 2024

DOI: 10.3802/jgo.2024.35.e98 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gynecologic Oncology, 2024. Verfasst von Chenlian Quan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. Hauptthemen laut MEDLINE: Sarcoma, Endometrial Stromal, Neoplasm Recurrence, Local, Endometrial Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: As an indolent malignant tumor, the long-term management of low-grade endometrial stromal sarcoma (LGESS) patients required awareness, especially the management of recurrences. Unfortunately, few studies focused on the treatment of recurrent LGESS. Our study aimed to investigate the prognostic factors and the value of recurrent surgery on recurrent LGESS. METHODS: This retrospective study consecutively recruited patients with pathologically diagnosed recurrent LGESS at our center from April 1, 2004 to April 1, 2020. RESULTS: After a median follow-up of 137.0 months (95% confidence interval=85.4-188.6), the 5-year cumulative survival rate of the cohort of 38 patients with recurrent LGESS was 71.1%. The median overall survival (OS) and post-recurrence survival (PRS) was 156 and 89.0 months. Survival analysis showed that patients with younger age, positive estrogen receptor (ER) and optimal abdominopelvic debulking in the first recurrent surgery had better prognosis (p 0.05). CONCLUSIONS: The prognosis of recurrent LGESS was favorable. Optimal debulking of no residual tumor in abdominal and pelvic cavity should be the first choice of treatment for recurrent patients, while preservation of ovary or fertility should not be recommended.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sarcoma, Endometrial StromalNeoplasm Recurrence, LocalEndometrial NeoplasmsHumansFemaleRetrospective StudiesMiddle AgedAdultPrognosisAgedCytoreduction Surgical ProceduresNeoplasm GradingSurvival Rate

Stichwörter der Autor:innen

Endometrial Stromal TumorsPrognosisRecurrenceSurgery

Autor:innen und Institutionen

  • Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
  • Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. huangyan1168@aliyun.com.

ORCID-Profile: Chenlian Quan, Zhong Zheng, Siyu Cao, Yong Wu, Wei Zhang, Yan Huang

Zitieren

APA

Quan, C., Zheng, Z., Cao, S., Wu, Y., Zhang, W., & Huang, Y. (2024). The value of surgery and the prognostic factors for patients with recurrent low-grade endometrial stromal sarcoma: a retrospective study of 38 patients. Journal of Gynecologic Oncology. https://doi.org/10.3802/jgo.2024.35.e98

Vancouver

Quan C, Zheng Z, Cao S, Wu Y, Zhang W, Huang Y. The value of surgery and the prognostic factors for patients with recurrent low-grade endometrial stromal sarcoma: a retrospective study of 38 patients. Journal of Gynecologic Oncology. 2024. doi:10.3802/jgo.2024.35.e98

BibTeX
@article{Quan2024,
  author = {Quan, Chenlian and Zheng, Zhong and Cao, Siyu and Wu, Yong and Zhang, Wei and Huang, Yan},
  title = {The value of surgery and the prognostic factors for patients with recurrent low-grade endometrial stromal sarcoma: a retrospective study of 38 patients},
  journal = {Journal of Gynecologic Oncology},
  year = {2024},
  doi = {10.3802/jgo.2024.35.e98}
}
Kostenlos starten →